Results 121 to 130 of about 2,689 (213)

Yoda1‐Functionalized Nanozymes Coordinate Piezo1 Activation and Mitochondrial Protection to Reprogram the Diabetic Osteoimmune Micromilieu and Promote Vascularized Bone Repair

open access: yesAdvanced Science, EarlyView.
Diabetic bone defects remain a critical clinical challenge. A 3D‐printed BCPG‐MF@Y scaffold, embedding Yoda1‐functionalized manganese dioxide‐ferritin nanozymes, scavenges mtROS, suppresses the cGAS–STING pathway, and reverses cellular senescence, while Yoda1 activates Piezo1 to direct BMSCs fate to synergistically reprogram the osteoimmune ...
Qing‐Song Deng   +16 more
wiley   +1 more source

A ROS‐Responsive and Mucoadhesive Thermosensitive Hydrogel Encapsulated with Mizoribine for Synergistic Dry Eye Therapy

open access: yesAdvanced Science, EarlyView.
The ROS‐responsive in situ thermosensitive MZR@SPPP hydrogel system enables dual‐stage drug loading and sustained ocular delivery. Upon administration, it gelates at ocular surface temperature, enhancing ocular adhesion. By scavenging free radicals, restoring NRF2‐mediated antioxidant defense and mitochondrial homeostasis, and suppressing inflammatory ...
Danyi Qin   +13 more
wiley   +1 more source

Intercellular communication in the fern endosymbiotic cyanobacterium <i>Nostoc azollae</i>. [PDF]

open access: yesmBio
Sarasa-Buisán C   +5 more
europepmc   +1 more source

Inhibition of MEKK3 Prevents Cerebral Cavernous Malformation Progression Via Restoring Endothelial Integrity and Restricting Microglial Activation

open access: yesAdvanced Science, EarlyView.
In this study, we demonstrate that aberrant MEKK3 signaling in endothelial cells and microglia drives the progression of cerebral cavernous malformations (CCMs). Furthermore, we identify DPDH as a potent small‐molecule MEKK3 inhibitor with substantial therapeutic potential for CCM treatment.
Weiwei Zheng   +17 more
wiley   +1 more source

Bacteria‐Derived 1‐Allylpiperazine Alleviates Symptoms of Parkinson's Disease Model by Promoting Autophagy

open access: yesAdvanced Science, EarlyView.
Parkinson's disease currently has no disease‐modifying therapies. In Caenorhabditis elegans, Escherichia coli E8 alleviates α‐synuclein‐provoked PD‐related defects through its bioactive metabolite 1‐ALPP, which combats PD by triggering AMPK/mTOR/HLH‐30‐dependent autophagy and suppressing α‐synuclein LLPS‐mediated fibrillization.
Mingqin Qu   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy